THPO (drug)
| Clinical data | |
|---|---|
| Other names | 4,5,6,7-Tetrahydroisoxazolo[4,5-c]pyridin-3(2H)-one |
| Drug class | GABA reuptake inhibitor |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C6H8N2O2 |
| Molar mass | 140.142 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
THPO, also known as 4,5,6,7-tetrahydroisoxazolo[4,5-c]pyridin-3(2H)-one, is a relatively weak GABA reuptake inhibitor with some glial selectivity.[1][2] It is a synthetic and conformationally restrained analogue of the GABAA receptor agonist and weak GABA reuptake inhibitor muscimol (found in Amanita muscaria).[1] Unlike muscimol however, THPO is a selective GABA reuptake inhibitor and lacks GABAA receptor affinity.[3][2] The drug penetrates into the brain in newborn mice, but shows only very limited central penetration in animals with fully developed brains.[2] Other structurally related selective GABA reuptake inhibitors include guvacine, nipecotic acid, and tiagabine.[1][2]
See also
- Gaboxadol (THIP)
References
- ^ a b c Krogsgaard-Larsen P, Frølund B, Frydenvang K (August 2000). "GABA uptake inhibitors. Design, molecular pharmacology and therapeutic aspects". Current Pharmaceutical Design. 6 (12): 1193–1209. doi:10.2174/1381612003399608. PMID 10903390.
- ^ a b c d Høg S, Greenwood JR, Madsen KB, Larsson OM, Frølund B, Schousboe A, et al. (2006). "Structure-activity relationships of selective GABA uptake inhibitors". Current Topics in Medicinal Chemistry. 6 (17): 1861–1882. doi:10.2174/156802606778249801. PMID 17017962.
- ^ Clausen RP, Madsen K, Larsson OM, Frølund B, Krogsgaard-Larsen P, Schousboe A (2006). "Structure–Activity Relationship and Pharmacology of γ-Aminobutyric Acid (GABA) Transport Inhibitors". Structure-activity relationship and pharmacology of gamma-aminobutyric acid (GABA) transport inhibitors. Advances in Pharmacology. Vol. 54. pp. 265–284. doi:10.1016/s1054-3589(06)54011-6. ISBN 978-0-12-032957-1. PMID 17175818.